Company Overview - MedRhythms, Inc. is pioneering next-generation neurotherapeutics aimed at improving walking, mobility, and related functional outcomes through a proprietary technology platform that integrates sensors, software, and music with advanced neuroscience [5] - The company has developed a pipeline of products targeting various neurological conditions, including stroke, multiple sclerosis, and Parkinson's disease [5] Leadership Transition - Larry Jasinski has been appointed as the new Chief Executive Officer, effective immediately, succeeding co-founder Brian Harris, who will transition to Chief Scientific Officer [1][3] - Jasinski brings over 30 years of executive leadership experience in the medical device and neurotechnology industries, including a successful IPO at Lifeward and national reimbursement for the first exoskeleton system for spinal cord injury [2] Strategic Growth Plans - The appointment of Jasinski is seen as a critical inflection point for MedRhythms, as the company prepares for national expansion of its home-use products, InTandem® for chronic stroke and Movive™ for Parkinson's disease, both of which are FDA-listed Class II devices [4] - The company aims to accelerate market adoption and build on its clinical foundation to reach more patients with chronic health and mobility conditions [4] Market Position and Vision - MedRhythms has established clinical data supporting the effectiveness of its products and operates in sizable market segments, having gained coverage from CMS and other entities [4] - The company is focused on transforming patients' lives and is positioned to become a valuable business entity in the neurorehabilitation space [4]